Stratifying Critically Ill Patients for Novel Ferroptosis or Pyroptosis Intervention Strategies
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood sampling.
- Who it may be relevant to
- Registry conditions: Sepsis, Trauma Related Injuries, Subarachnoid Haemorrhage (SAH). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Innovative Cell Death Diagnostics Allowing Stratifying Critically Ill Patients for Novel Ferroptosis or Pyroptosis Intervention Strategies
Overview
In order to better determine which therapy is best for patiënts which present with organ falure during the course of their stay in the intesive care unit (ICU) , one has to determine which underlying mechanism is causing this organ falure. We will determine levels of so called "biomarkers" for ferroptosis (a mechan ism of iron-related cell death) in the peripheral blood and biological fluids of criticaly ill patients admitted to the ICU with a catastrrophy (severe infection, trauma ...) . Why ? If it turns out that this ferroptosis plays a role in the ocurrence of organ failure in the critially ill, this will lead to new therapies in the future as drugs become more and more available which can influene this biochemical "pahway". of iron-relatd death.
Interventions
- Diagnostic test Blood sampling
Blood sampling: 3 first days of admision, 2 ml of plasma daily Urine, BALF, CSF sampling: 1 day during 3 first days of admission
Primary outcome measures
- Number of patients with survival after 28 days. [Time frame: 28 days]
Secondary outcome measures (2)
- Change from baseline concentration of Norepinephrine every day during ICU stay [Time frame: 28 days]
- Change in SOFA score during ICU stay [Time frame: Change from enrollment to 14 days of ICU stay]
Eligibility criteria
Inclusion criteria
- Admitted to the ICU of UZA
- Critically ill and predicted to be hospitalised in the ICU for > 48 hours (i.e. mostly patients admitted for sepsis, trauma, haemorrhagic shock, neurological catastrophe … which means at risk to develop mono-or multiple organ failure)
- With arterial line in place (for blood sampling)
Exclusion criteria
- Refusal of consent by patient or closest relative
- Postoperative patients after major surgery in whom prolonged ICU stay is not foreseen (i.e. elective cardiac surgery
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
Belgium · 1 center
- University Hospital Antwerp — Edegem
Identifiers
NCT: NCT06928649 · EDGE 3060